Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.66M Buy
102,505
+2,147
+2% +$116K 0.6% 68
2025
Q4
$4.92M Buy
+100,358
New +$4.68M 0.53% 78
2023
Q3
Sell
-6,300
Closed -$225K 196
2023
Q2
$225K Hold
6,300
0.03% 190
2023
Q1
$224K Sell
6,300
-360
-5% -$12.6K 0.03% 181
2022
Q4
$234K Buy
+6,660
New +$222K 0.03% 183
2022
Q3
Sell
-6,786
Closed -$369K 191
2022
Q2
$369K Buy
+6,786
New +$375K 0.05% 157
2020
Q4
Sell
-8,873
Closed -$417K 179
2020
Q3
$417K Sell
8,873
-247
-3% -$12.4K 0.06% 132
2020
Q2
$465K Sell
9,120
-357
-4% -$18.3K 0.07% 115
2020
Q1
$449K Sell
9,477
-880
-8% -$46.9K 0.08% 119
2019
Q4
$608K Buy
+10,357
New +$576K 0.08% 117
2013
Q4
Sell
-7,608
Closed -$477K 251
2013
Q3
$477K Sell
7,608
-921
-11% -$59.3K 0.04% 278
2013
Q2
$533K Buy
+8,529
New +$541K 0.05% 289

Other funds holding GSK

Leuthold Group's GSK Position: Q1 2026 in Review

Leuthold Group increased its GSK (GSK) stake by 2.1% in Q1 2026, buying an estimated $116K and bringing the position to 102,505 shares worth $5.66M. The position accounts for 0.6% of the portfolio, ranked #68.

Leuthold Group first reported a position in GSK in Q2 2013 and has held it in 12 quarters since. 1,032 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Leuthold Group held 102,505 shares of GSK worth $5.66M as of Q1 2026.
  • Leuthold Group bought 2,147 GSK shares in Q1 2026, an estimated $116K.
  • GSK made up 0.6% of Leuthold Group's portfolio in Q1 2026, its #68 holding.
  • Leuthold Group first reported a position in GSK in Q2 2013 and has held it in 12 quarters since.
  • 1,032 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Leuthold Group's 13F filing for Q1 2026, filed 6 May 2026.